Valuation: Celcuity Inc.

Market Cap 4.52B 3.91B 3.65B 3.35B 6.31B 431B 6.41B 42.88B 16.83B 216B 16.99B 16.62B 714B P/E 2026 *
-22x
P/E 2027 * -184x
Enterprise Value 4.52B 3.91B 3.65B 3.35B 6.31B 431B 6.41B 42.88B 16.83B 216B 16.99B 16.62B 714B EV / Sales 2026 *
116x
EV / Sales 2027 * 11.5x
Free-Float
83.37%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Celcuity Inc.

1 day-0.50%
1 week+7.41%
Current month+7.41%
1 month-14.80%
3 months-29.21%
6 months-13.09%
Current year-6.98%
1 week 83.43
Extreme 83.4284
95.2
1 month 78.6
Extreme 78.6
113.73
Current year 78.6
Extreme 78.6
151.02
1 year 44.42
Extreme 44.42
151.02
3 years 7.58
Extreme 7.575
151.02
5 years 4.81
Extreme 4.81
151.02
10 years 4.03
Extreme 4.03
151.02
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 64 01/01/2012
Chief Executive Officer 64 01/01/2012
Director of Finance/CFO 59 01/07/2017
Director TitleAgeSince
Chairman 64 01/01/2012
Director/Board Member 64 01/01/2012
Director/Board Member 67 01/02/2014
Date Insider Type Main position Quantity % Market Cap.
14/07/26
Baker Bros. Advisors LP
SellCompany -3,100,000 6.6996%
02/06/26 Fiscal year

Founder

2,000 0.0043%
09/04/26 Don

Director

10,000 0.0216%
Change 5-day change 1-year change 3-year change Capi.($)
-0.50%+7.41%+102.22%+826.87% 4.52B
+8.49%+20.55%+70.77%+110.32% 68.12B
+1.25%+2.44%+34.27%+70.43% 55.18B
-1.09%+32.96%+19.67%+494.56% 28.63B
+10.83%+18.38%+56.20%+6.03% 23.99B
+2.72%+3.41%-16.11%-7.96% 23.53B
+6.50%+7.56%+44.65%-21.73% 18.45B
+6.20%+11.51%+33.87%+693.38% 16.44B
-3.88%+16.98%+199.30%+359.77% 15.83B
+3.58%+1.96%+43.35%+163.76% 13.4B
Average +3.41%+11.25%+58.82%+269.54% 26.81B
Weighted average by Cap. +4.27%+13.00%+51.56%+179.59%

Financials

2026 *2027 *
Net sales 38.92M 33.66M 31.44M 28.84M 54.24M 3.7B 55.1M 369M 145M 1.86B 146M 143M 6.14B 393M 340M 318M 291M 548M 37.42B 557M 3.73B 1.46B 18.76B 1.48B 1.44B 62.01B
Net income -221M -191M -179M -164M -308M -21.04B -313M -2.1B -822M -10.55B -830M -812M -34.86B -34.43M -29.78M -27.81M -25.51M -47.99M -3.28B -48.75M -326M -128M -1.64B -129M -126M -5.43B
Net Debt - -
Logo Celcuity Inc.
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors.
Employees
155
Date Price Change Volume
07/08/26 $92.78 -0.50% 543,219
06/08/26 $93.25 +0.36% 569,612
05/08/26 $92.92 +0.46% 772,006
04/08/26 $92.49 +5.44% 713,927
03/08/26 $87.72 +1.55% 557,345
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
92.78USD
Average target price
163.54USD
Spread / Average Target
+76.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CELC Stock